Torun

• Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I … Ended
  2023-507569-24-00 4 2022-06-20 Myocardial Infarction, Acute Heart Failure, Left Sided
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153 … Ended
  2023-510172-31-00 5 2022-04-22 Chronic obstructive pulmonary disease (COPD)
• Evaluation of safety i efficacy de-escalation antiplatelet strategies in acute coronary syndrome. Ended
  2024-518090-34-00 5 2022-02-07 Acute Coronary Syndrom (ACS)
• MENACWY=MEN7B-003 Ended
  2023-506449-40-00 9 2021-11-29 Infections, Meningococcal
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended
  2024-517389-40-00 4 2021-10-06 acute lymphoblastic leukemia
• Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Und … Ended
  2024-515056-20-00 5 2021-07-31 Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoin
• Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended
  2023-509937-37-00 4 2021-07-21 Osteoarthritis
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17 Chronic Obstructive Pulmonary Disease (COPD)
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust … Ended
  2023-504977-19-00 5 2021-03-15 Moderately to Severely Active Ulcerative Colitis
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien … Ended
  2023-507415-35-00 5 2021-01-15 Psoriatic Arthritis
• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansi … Ended
  2024-516691-14-00 7 2021-01-05 B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocy
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended
  2023-506527-28-00 5 2020-06-29 Axial Spondyloarthritis
• Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended
  2023-507024-24-00 5 2020-05-05 Metastatic hormone sensitive prostate cancer
• Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended
  2022-501018-78-00 5 2020-03-23 Axial Spondyloarthritis
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Re … Ended
  2024-515123-11-00 3 2019-09-05 Lymphoma
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended
  2024-515051-38-00 5 2018-07-20 Non-small Cell Lung Cancer
• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Ended
  2024-515052-20-00 5 2017-09-20 Non-small Cell Lung Cancer

Showing 217–240 of 246 trials